The Synthesis and Anti-Bacterial Activities of N-carboxymethyl Rhodanines

Ming-Xia Song¹, Chang-Ji Zheng², Xian-Qing Deng¹, Zhi-Yu Wei² and Hu-Ri Piao∗

¹JingGangshan University College of Medicine, J’an 343100, P R China
²Key Laboratory of Natural Resources and Functional Molecules of the Changbai Mountain, Affiliated Ministry of Education; Yanbian University College of Pharmacy, Yanji 133002, P R China

Abstract

A large number of reports have been published in recent years regarding the use of N-carboxymethyl rhodanines as antimicrobial agents. Molecules belonging to this structural class have been reported to exhibit good inhibitory activities towards various Gram-positive bacteria, including several multidrug-resistant strains such as methicillin-resistant Staphylococcus aureus and quinolone-resistant Staphylococcus aureus. In this mini-review, we have provided a summary of recent research directed towards the synthesis of N-carboxymethyl rhodanines, and their pharmacological evaluation as antimicrobial agents.

Keywords: Synthesis; Antibacterial activity; Methicillin-resistant Staphylococcus aureus; Quinolone-resistant Staphylococcus aureus; N-carboxymethyl rhodanine; Chalcone

Introduction

The treatment of bacterial infections currently represents a significant therapeutic challenge throughout the world. Although antibiotics are still available for most common infections, the emergence of new infectious diseases—as well as increasing levels of resistance in some pathogens—threaten to undermine the effectiveness of the few remaining drugs available for the treatment of these infections [1,2].

Heterocyclic compounds have been used extensively in the field of medicinal chemistry, where they occupy a central position in the development of new and novel therapeutic agents. Rhodanines are five-membered heterocyclic compounds, which have a sulfur atom at their 1-position, a thiocarbonyl group at their 2-position, a nitrogen atom at their 3-position, and a carbonyl group at their 4-position. These compounds belong to an interesting class of heterocyclic molecules, which have attracted considerable attention from chemists over the last 20 years because of their wide range of biological properties, including their antibacterial [4-9], antifungal [10-13], anti-diabetic [14-16], anti-inflammatory [17-18], antituberculosis [19], anticancer [20,21], anti-HIV [22,23], antiparasitic [24], hypnotic [25], and antimeltic [26,27] activities.

Although several reviews have been published concerning the chemistry and biological activities of rhodanines [28,29], there have been no reviews in the literature pertaining to the anti-bacterial properties of N-carboxymethyl rhodanines. In the current review, we provide a summary of recent research progress towards the synthesis of N-carboxymethyl rhodanines, with particular emphasis on the antibacterial activities of these compounds.

Preparation of N-Carboxymethyl Rhodanines

Several methods have been reported in the literature for the synthesis of rhodanines, and these methods are also applicable to the synthesis of N-carboxymethyl rhodanines. There are several different strategies available for the synthesis of N-substituted rhodanines, which generally involve the use of three specific components, including a substituted-amine, carbon disulfide and chloroacetic acid. N-Substituted rhodanines have traditionally been synthesized according to a one-pot three-component condensation reaction (Scheme 1) [30-32]. This particular reaction begins with the nucleophilic attack of the carbon of carbon disulfide by the amine to give a thioamide. The resulting sulfur nucleophile then reacts with chloro- or bromo-acetic acid, followed by intramolecular cyclization with loss of water to give the desired rhodanine. It is important to note, however, that the amenability of this method to high throughput synthesis has been limited by its requirement for harsh reaction conditions and extended reaction times.

To address some of the issues associated with this reaction, Nitsche and Klein [32] reported the development of an improved one-pot process for the synthesis of N-aryl rhodanines by the reaction of bis(carboxymethyl)trithiocarbonate with anilines in water under microwave irradiation (Scheme 2). This particular method allowed for alkyl- and benzyl-aminos to be converted to the corresponding rhodanines in an atom-efficient manner according to a one-pot, three-step protocol based on carbon disulfide and chloroacetic acid in short reaction times and good to excellent yields.

Alizadeh et al. [33] reported the development of a simple and effective one-pot procedure for the synthesis of rhodanine derivatives using commercially available starting materials with water as a solvent (Scheme 3). The authors of this particular study also provided experimental evidence in support of their proposed reaction mechanism for the reaction of the amine with carbon disulfide in the presence of DDAP. As shown in Scheme 4, the proposed mechanism suggested that the initial addition of the amine to carbon disulfide would result in the formation of the reactive alkylammonium carbodithioate 4, which would react with the acetylenic ester 2 to yield intermediate 5.

*Corresponding author: Hu-Ri Piao, Yanbian University College of Pharmacy, Yanji, Jilin 133002, P R China, Tel: + 86-433-2435003; Fax: + 86-433-2435028; E-mail: piaohun@aliyun.com

Received April 21, 2014; Accepted May 21, 2014; Published May 23, 2014


Copyright: © 2014 Song MX, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Subsequent cyclization of 5 would occur with the loss of R'OH to give compound 3 [34].

Singh and Chauhan [35] reported a novel multi-component process for the synthesis of ketene dithioacetal rhodanines involving the reaction of a primary amine with carbon disulfide, ethyl chloroacetate, and an alkyl halide in DMF (Scheme 5). The authors of this study also investigated the effects of different bases on the performance of the reaction and found that potassium carbonate provided the best results of all of the bases tested, affording moderate to good yields of the desired products at room temperature [35].

**Antibacterial Activity of N- Carboxymethyl Rhodanines**

The anti-microbial activity of rhodanines has been known for over 50 years, and numerous studies have been reported involving the design and synthesis of anti-bacterial agents based on this heterocycle [36-39]. Furthermore, there has been a recent increase in the number of reports concerning the anti-bacterial activities of N-carboxymethyl rhodanines (Figure 1). Herein, we have provided a summary of recent reports pertaining to the anti-bacterial activities of N-carboxymethyl rhodanines.

Methicillin-resistant *Staphylococcus aureus* (MRSA) has become commonly resistant to most available antibiotics.
a major threat to human health throughout the world. It has been estimated that more than 50% of all staphylococcus infections are caused by MRSA. Furthermore, most strains of MRSA are resistant to β-lactam and macrolide/azalide antibiotics. Although some MRSA infections can be treated, the resistance rates are increasing, and there is therefore an urgent need to develop new therapeutic agents against MRSA with high levels of potency. Hardej et al. [40] reported the synthesis of a series of N-carboxymethyl-5-arylmethylidenerhodanines, which were screened for their activity against MRSA (Figure 2) [40].

Two of these compounds (1a and 1b) exhibited higher levels of activity towards MRSA (MICs of 1.95 and 3.9 µg/mL) than the reference antibiotic ciprofloxacin (MIC 7.8 µg/mL). Furthermore, the activities of these compounds towards MRSA were not affected by the absence or presence of 10% FBS.

Patel et al. [41] synthesized a series of C5-analogues of compound 1b in attempt to identify the optimal C5-arylidene substituent. All of the rhodanine analogues synthesized in this study were tested for their in vitro activity against a panel of MRSA strains, including MRSA ATCC 34404, MRSA ATCC 700787, MRSA ATCC 700698, MRSA ATCC BAA-39, MRSA CA ATCC BAA-1680 and MRSA ST239 HS770. The SAR data for these compounds clearly emphasized the importance of a hydrophobic aromatic substituent on the benzylidene moiety. Three compounds (2a–c) exhibited improved efficacy over 1b against MRSA ATCC 34404 with an MIC value of 0.98 µg/mL (Figure 3).

Peptidoglycan is an essential cell-wall polymer unique to prokaryotic cells that provides the rigidity, flexibility and strength required for bacterial cells to grow and divide, whilst withstanding the high internal osmotic pressure. Several Mur enzymes (MurC–F) were discovered to be involved in the early intracellular stages of cytoplasmic peptidoglycan precursor biosynthesis. For this reason, the bacterial Mur ligases became new targets for anti-bacterial drug discovery. Tomasić et al. [42] prepared a series of hydroxy-substituted 5-benzylidenethiazolidin-4-ones as Mur ligase inhibitors. The IC₅₀ values of the representative inhibitor 3 towards MurE and MurF were 19 and 6 µM, respectively. Unfortunately, however, compound 3 was found to be a weak inhibitor of bacterial growth in vitro with an MIC value of 128 µg/mL against two strains of Gram-positive bacteria (i.e., S. aureus ATCC 29213 and Enterococcus faecalis ATCC 29212). Furthermore, compound 3 exhibited an MIC value of >128 µg/mL towards two strains of Gram-negative bacteria (i.e., E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853). Compound 4, which was prepared to provide improved LogP properties over compound 3, gave the same results with MIC values >128 µg/mL against all of the bacterial strains tested in the study (Figure 4) [43].

Alegaoan and Alagawadi [44] reported the synthesis of hybrid molecules of imidazo[1,3,4]thiadiazoles and N-carboxymethyl rhodanine and the subsequent evaluation of their antibacterial activities. Compound 5 is representative of this series and showed significant activity against S. aureus (MIC=4 µg/mL), as well as moderate activity against E. coli (MIC=32 µg/mL) (Figure 5). Furthermore, compound 5 showed good antifungal activity against several strains of fungi, including Candida albicans (ATCC 2091), Aspergillus flavus (NCIM No. 524), Aspergillus niger (ATCC 6275), and Cryptococcus neoformans (clinical isolate).

Based on the potential antibacterial activities of N-carboxymethyl rhodanines and their amenability to structural modification, our group started a new project aimed at designing novel antibacterial agents with an N-carboxymethyl rhodanine nucleus. In 2009, we synthesized a series of hybrid compounds containing chalcone and N-carboxymethyl rhodanine moieties (6a–s) with the aim of harnessing the antibacterial activities of both chalcones and N-carboxymethyl rhodanines (Figure 6) [45]. In this particular study, the target compounds were prepared in good yields by the Knoevenagel condensation of a range of (E)-4-(3-substitutedphenyl-3-oxoprop-1-enyl)benzaldehydes with N-carboxymethyl rhodanine. Subsequent pharmacologic evaluation revealed that some of these compounds possessed significant antibacterial activities towards a range of Gram-positive bacteria, including S. aureus RN 4220, S. aureus KTCT 503, S. aureus KTCT 209, S. mutans KTCT 3065 and S. mutans KTCT 3289. Furthermore, derivative 6k, which had an MIC value of 2 µg/mL against all of these...
strains, was as active as the standard drug norfloxacin. However, none of these compounds exhibited inhibitory activity towards the growth of the Gram-negative bacteria _E. coli_ CCARM 1924 and _E. coli_ CCARM 1356 at 32 µg/mL. Analysis of the SAR of this series of compounds revealed that those bearing electron-donating groups showed lower levels of activity than those bearing electron- withdrawing halogen substituents (e.g., 6a, 6d vs 6g, 6i), and that _para_-substituted derivatives displayed better activity than the corresponding _ortho_-substituted compounds (6g, 6i vs 6d, 6h) (Figure 6).

Although some of the chalcone-based _N_-carboxymethyl rhodanines were found to possess promising antibacterial activities, very little is still known about these compounds in terms of identifying which parts of their structures are essential to their antibacterial activity, despite some limited SAR. With this in mind, Jin et al. [46] designed and synthesized a series of chalcone derivatives containing _N_-substituted rhodanine (7a–e) and evaluated their antimicrobial activities against several different strains of bacteria (Figure 7). Some of the compounds in this series were found to be inactive against the bacteria evaluated in this study at 64 µg/mL. These data therefore supported the importance of the presence of the _N_-carboxymethyl moiety in terms of delivering potent antibacterial activity.

Based on the results of these experiments, Jin et al. [46] synthesized several chalcone analogues bearing an _N_-carboxymethyl rhodanine (9a–q) and tested their antibacterial activities against several different strains of bacteria (Figure 7). These particular compounds exhibited significant levels of antibacterial activity with MIC values in the range of 2–16 µg/mL. Several other compounds, including compounds 8a–j and 9a–q were synthesized and exhibited significant levels of activity against _MRSA_ CCARM 3167, _MRSA_ CCARM 3506, _QRSA_ CCARM 3505 and _QRSA_ CCARM 3519, with MIC values in the range of 2–8 µg/mL. These data demonstrated that the introduction of a hydrophobic side chain on the _N_-carboxymethyl moiety of the rhodanine led to significant increases in the potency compared with the previously reported compounds (6a–s), especially against the multidrug-resistant clinical isolates.

To establish comprehensive SAR and obtain new and improved antibiotics, several groups continued to work towards the modification of chalcones bearing _N_-carboxymethyl rhodanines, and two series of optical isomers (10a–i and 11a–i) were designed and synthesized to investigate the impact of the stereocchemistry (i.e., _R_ - or _S_ -) on the anti-bacterial activity of the compounds (Figure 8) [47]. The majority of these compounds showed good levels of inhibition with MIC values in the range of 1–16 µg/mL against _S. aureus_. In particular, compounds 10g and 10h (MIC=1 µg/mL) were two-fold more potent than the positive control norfloxacin (MIC=2 µg/mL) against _S. aureus_ RN 4220. These compounds also exhibited good inhibitory activity against _MRSA_ CCARM 3167 and 3506, with an MIC value of 1 µg/mL. The results from this study effectively confirmed that the stereocchemical configuration had no impact on the anti-bacterial activity of these compounds. In a separate study, several alternative _N_-carboxymethyl side chains were designed and attached to the chalcone bearing _N_-carboxymethyl rhodanines to give compounds 12a–n and 13a–n (Figure 9). These compounds also displayed promising antimicrobial activities against several Gram-positive strains of bacteria and multidrug-resistant clinical isolates, including _S. aureus_ RN 4220, _S. aureus_ KCTC 209, _S. aureus_ KCTC 503, _MRSA_ CCARM 3167 and 3506, _QRSA_ CCARM 3505 and 3519 [48].

At the same time, we also prepared a series of (Z)-5-[4-[2-(2-substituted phenyl)-2-oxoethoxy] benzyldiene]-2-thioxothiazolidin-4-ones (14a–m) by changing the chalcone moiety to a 4-(2-oxo-2-phenylethoxy)benzene in the compound 6k whilst simultaneously introducing different substituents to the terminal phenyl ring (Figure 10) [49]. This design aimed to reduce the rigidity of the chalcone moiety in 6k with the expectation that this would afford enhanced levels of binding to the receptor and greater activity. Furthermore, the acetic acid group at the 3-position of the rhodanine was removed completely or replaced with different aromatic amino acid side chains (including L-phenylalanine, L-tyrosine and L-tryptophan), which resulted in four different series of compounds (15a–m, 16a–m, 17a–m and 18a–m) (Figure 10).

All of the synthesized compounds were screened for their activity against three different strains of Gram-positive bacteria (i.e., _S. aureus_ RN 4220, _S. aureus_ KCTC 209 and _S. aureus_ KCTC 503) and one strain of Gram-negative bacteria (i.e., _Escherichia coli_ 1356). Most of the synthesized compounds showed potent inhibitory activity against the three strains of Gram-positive bacteria with MIC values in the range of 1–32 µg/mL. Compound 18c, bearing a 4-Cl substituent on its terminal phenyl ring, exhibited the highest level of activity with an MIC value of 1 µg/mL against all three of the Gram-positive strains. The inhibitory activities of these compounds were also tested against several clinical isolates of multidrug-resistant Gram-positive bacteria, including _MRSA_ CCARM 3167, _MRSA_ CCARM 3506, _QRSA_ CCARM 3505 and _QRSA_ CCARM 3519, and compounds 16i, 18b and 18c were found to be the most potent, with MIC values of 1 µg/mL against all of these multidrug-resistant strains. SAR analysis of the compounds synthesized in this study also revealed several trends, including (I) the _N_-carboxymethyl moiety was necessary for anti-bacterial activity against Gram-positive bacteria; and (II) the inclusion of a phenethyl moiety or other hydrophobic substituent at the _N_-carboxymethyl moiety was necessary to increase the antibacterial activity.

In a subsequent study, we continued with our work towards the modification of _N_-carboxymethyl rhodanines by introducing different groups at the 5-position of these compounds to give four different series of analogues, including 19a–x, 20a–t, 21a–p and 22a–x (Figure 11) [50–53]. The antimicrobial activities of all of the compounds were evaluated against several different strains of bacteria, including multidrug-resistant clinical isolates. In their respective series, compounds 19k, 20g, 21c, and 22l, bearing 4-Br, 4-CF$_3$, 4-Cl, and 2,5-CI substituents, respectively, exhibited the strongest antimicrobial activities with MIC values of 1, 1.8, and 2 µg/mL against _MRSA_ CCARD 3167/3506 or _QRSA_ CCARM 3505/3519, respectively.
Molecules containing a pyrazole ring are known to possess a wide variety of biological activities [54,55], and there has been a recent increase in studies directed towards the use of pyrazole derivatives as potential antimicrobial agents [56-60]. With this in mind, we designed and synthesized a new series of pyrazole-based N-carboxymethyl rhodanines (23a–p) and evaluated their antimicrobial activity (Figure 12) [61]. Compounds 23f, 23i, and 23o showed the highest antimicrobial activities of these compounds with MIC values of 8 µg/mL against...
S. aureus RN 4220 and S. aureus KCTC 503. To further improve the activities of these pyrazole-based N-carboxymethyl rhodanines, we also synthesized compounds 24a–o via the addition of a benzyl moiety to the N-carboxymethyl group (Figure 12) [62]. Among the synthesized compounds, compounds 24a–d and 24m showed high levels of activity towards S. aureus RN 4220 and S. aureus KCTC 503, with MIC values of 2 µg/mL. Compounds 24b, 24d, 24g, 24h, 24j and 24m showed significant levels of activity towards MRSA 3167 and MRSA 3506 with MIC values in the range of 2–8 µg/mL. In contrast, compounds resistant Gram-positive strains (MRSA 3167 and MRSA 3506) with levels of inhibitory activity towards S. aureus RN 4220 and multidrug-resistant clinical isolates (including several multidrug-resistant clinical isolates). It is envisaged that further improvements will be made to the skeleton in the near future to obtain novel antibacterial agents.

Acknowledgements

This work was supported by the National Science Foundation of China (Grant no. 81260468). We would like to express our gratitude to the members for their contribution to N-carboxymethyl rhodanines studies over the years.

References


Conclusion

In summary, several different series of N-carboxymethyl rhodanines have been synthesized and evaluated for their antibacterial activities. Compounds belonging to these series have been the subject of considerable interest from chemists and biologists, because of their high levels of activity against Gram-positive strains (including several multidrug-resistant clinical isolates). It is envisaged that further improvements will be made to the skeleton in the near future to obtain novel antibacterial agents.

S. aureus RN 4220 and S. aureus KCTC 503. To further improve the activities of these pyrazole-based N-carboxymethyl rhodanines, we also synthesized compounds 24a–o via the addition of a benzyl moiety to the N-carboxymethyl group (Figure 12) [62]. Among the synthesized compounds, compounds 24a–d and 24m showed high levels of activity towards S. aureus RN 4220 and S. aureus KCTC 503, with MIC values of 2 µg/mL. Compounds 24b, 24d, 24g, 24h, 24j and 24m showed significant levels of activity towards MRSA 3167 and MRSA 3506 with MIC values in the range of 2–8 µg/mL. In contrast, compounds resistant Gram-positive strains (MRSA 3167 and MRSA 3506) with levels of inhibitory activity towards S. aureus RN 4220 and multidrug-resistant clinical isolates. It is envisaged that further improvements will be made to the skeleton in the near future to obtain novel antibacterial agents.

Acknowledgements

This work was supported by the National Science Foundation of China (Grant no. 81260468). We would like to express our gratitude to the members for their contribution to N-carboxymethyl rhodanines studies over the years.

References


